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Imidazoacridinones are a new class of potent antineoplastic agents
which have been developed by Konopa and co-workers at the
Technical University of Gdansk, Poland (Cholody et al, 1990,
1992). The design of these compounds was based on
structure–activity relationship studies of the chemotherapeutic
agent mitoxantrone. The diaminoalkyl groups (‘daag’) in the side-
chains of mitoxantrone had previously been found to be a pre-
requisite for the biological activity of this drug (Konopa and
Skladanowski, 1987; Cheng and Cheng, 1989). The attachment of
daag to known DNA-intercalating acridinone moieties resulted in
the C13xx imidazoacridinone series of compounds, which showed
anti-tumour activity in vitro and in vivo in various tumour model
systems (Kusnierczyk et al, 1994).
We have recently reported that the most potent imidazoacridi-
none analogue, C1311 (Figure 1), induces inhibition of experi-
mental human and murine colorectal cancer cell growth. The
human colon cancer xenograft HT29 showed marked tumour
growth delay (100mg kg–1 = 211.4%, P< 0.001) after a single-
dose intraperitoneal (i.p.) bolus injection (Burger et al, 1996).
Based on these and other xenograft data (unpublished) obtained by
European Organisation for Research and Treatment of Cancer and
Screening and Pharmacology Group (EORTC-SPG) screening
laboratories, C1311 was selected for further evaluation and will
soon enter clinical phase I trials.
Several groups have been studying possible mechanisms under-
lying the antiproliferative activity of C1311 in vitro and most
reports describe the cellular response as being associated with
DNA-related events or damage, including DNA binding (Berger
et al, 1996; Burger et al, 1996), topoisomerase II inhibition
(Skladanowski et al, 1996) and G2 arrest (Augustin et al, 1996;
Lamb and Wheatley, 1996). However, due to the fluorescent
nature of imidazoacridinone derivatives, we and others followed
the cellular distribution of these compounds and observed the
rapid accumulation of C1311 fluorescence not only in nuclei, but
also in other cytoplasmic organelles (Berger et al, 1996; Burger et
al, 1996; Skladanowski et al, 1996).
The present study was designed to define the cytosolic compart-
ment and the relevance of the involvement of these organelles in
the anti-tumour efficacy of C1311. Cellular uptake and the mecha-
nism by which C1311 interacts with DNA and exerts cytotoxic
effects in intact colon carcinoma cells were investigated. We
describe the cellular mechanisms of C1311 in relation to its struc-
tural features supporting that DNA intercalation and lysosomal
rupture are the lethal lesions induced at drug concentrations
causing total growth inhibition in HT29 colon cancer cells.
Moreover, the lysosomotropic effect of C1311 might be a critical
component for C1311 therapeutic efficacy against colorectal
cancer in vitro and in vivo.
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SummaryC1311 is a novel therapeutic agent with potent activity against experimental colorectal cancer that has been selected for entry into
clinical trial. The compound has previously been shown to have DNA-binding properties and to inhibit the catalytic activity of topoisomerase
II. In this study, cellular uptake and mechanisms by which C1311 interacts with DNA and exerts cytotoxic effects in intact colon carcinoma
cells were investigated. The HT29 colon cancer cell line was chosen to follow cellular distribution of C1311 over a time course of 24h at drug
concentrations that just inhibited cell proliferation by 50% or 100%. Nuclear uptake of C1311 and co-localization with lysosomal or
mitochondrial dyes was examined by fluorescence microscopy and effects on these cellular compartments were determined by measurement
of acid phosphatase levels, rhodamine 123 release or DNA-binding behaviour. The strength and mode of DNA binding was established by
thermal melting stabilization, direct titration and viscometric studies of host duplex length. The onset of apoptosis was followed using a
TUNEL assay and DNA-fragmentation to determine a causal relationship of cell death. Growth inhibition of HT29 cells by C1311 was
concomitant with rapid drug accumulation in nuclei and in this context we showed that the compound binds to duplex DNA by intercalation,
with likely A/T sequence-preferential binding. Drug uptake was also seen in lysosomes, leading to lysosomal rupture and a marked increase
of acid phosphatase activity 8h after exposure to C1311 concentrations that effect total growth inhibition. Moreover, at these concentrations
lysosomal swelling and breakdown preceded apoptosis, which was not evident up to 24h after exposure to drug. Thus, the lysosomotropic
effect of C1311 appears to be a novel feature of this anticancer agent. As it is unlikely that C1311-induced DNA damage alone would be
sufficient for cytotoxic activity, lysosomal rupture may be a critical component for therapeutic efficacy.
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Materials/Drugs
The 5-(w-aminoalkyl)amino-8-hydroxyimidazoacridinone C1311
(Figure 1) was synthesized at the Technical University of Gdansk,
as described elsewhere (Cholody et al, 1990, 1992). Stock solu-
tions were prepared in dimethyl sulphoxide (DMSO) or normal
saline. Aqueous solutions were prepared in polystyrene tubes to
minimize adsorption effects and quantified by spectrophoto-
metry. Hoechst 33258 dye (Sigma-Aldrich Ltd) was used as a
control ligand for viscometric studies and quantified using e338 =
42 000 M–1 cm–1 (Loontiens et al, 1990). All DNA binding experi-
ments were performed in aqueous phosphate buffer (10 mM
NaH2PO4/Na2HPO4, 1 mM Na2EDTA, pH 7.00 ± 0.01). Double-
stranded calf thymus DNA (CT-DNA, type-I [Sigma-Aldrich
Ltd.]) was sonicated and purified using a published procedure
(Chaires et al, 1982), then dialysed for 48 h against phosphate
buffer using a MW 10 000 cut-off membrane to remove short frag-
ments. This procedure results in duplex DNA with an average
length of ~200 bp (~100 kDa) necessary for viscometric studies to
ensure that the DNA behaves like a stiff rod and to minimize
effects from changes in persistence length (Chaires et al, 1982).
CT-DNA solutions were quantified spectrophotometrically using
e260 = 12 824 M(bp)–1 cm–1.
Lyso trackerTM and Mito trackerTM were obtained from
Molecular Probes Europe (Leiden, The Netherlands). Rhodamine
123 dyes and all other chemicals or reagents used were purchased
from Sigma-Aldrich Ltd (Poole, Dorset, UK). Tissue culture
medium and supplements were purchased from Life Technologies
(Paisley, UK) and Costar Ltd (High Wycombe, UK).
Cell culture and in vitro cytotoxicity assay
The human colon cancer cell line HT29 was obtained from the
central repository of the National Cancer Institute in vitro cell line
screening programme (Frederick, MD, USA) and was routinely
maintained as monolayer culture in RPMI-1640 medium supple-
mented with 10% fetal calf serum and 2 mML -glutamine in a
humidified atmosphere containing 5% carbon dioxide at 37°C.
C1311 doses required to produce 50% (IC50) or total growth inhi-
bition (TGI), and the effects of drug concentration (C) and time
(T) on chemosensitivity, were determined using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetralium bromide (MTT) assay
procedure as described elsewhere (Burger et al, 1996; Nicholson
et al, 1997).
Measurement of DNA/C1311 complexes in HT29 cells
Exponentially growing HT29 cells were trypsinized and seeded
into 96-well plates (50 000 per well) 24 h prior to drug treatment.
Cells were then exposed to C1311 at IC50 (0.5 mM) and TGI
(2 mM) concentrations for 1, 4 and 8 h. Control cells were treated
with vehicle (saline) only. To measure complexes formed by
C1311 with genomic DNA, plates were washed twice with 200 ml
phosphate-buffered saline (PBS), and C1311 in DNA quantified
by using a fluorescence plate reader (Cytofluor 2300, Perkin-
Elmer). Fluorescence intensity of C1311-treated HT29 cells (in
100 ml PBS per well) was determined at 360/40 nm excitation and
530/25 nm emission filter settings.
Fluorescence microscopy studies
HT29 cells were grown on glass slides to follow the intracellular
distribution of C1311 at various time points: 30 min, 1 h, 4 h, 8 h,
16 h and 24 h. Exponentially growing cells were treated with
0.5 mM (approx. IC50) or 2.0 mM (approx. TGI) drug respectively.
Localization of inherent C1311 fluorescence (excitation/emission
maxima = 340/520 nm) was compared to the lysosomal paint,
Lyso trackerTM (final concentration 200 nM), and the mitochondrial
stains rhodamine 123 (10 mg ml–1) and Mito trackerTM (final
concentration 200 nM) after short-term (30 min) exposure. In
addition, C1311 was co-cultured with each of these dyes. Cells
were washed three times with ice-cold PBS to remove background
for microscopic examination and kept at 4°C. Intracellular fluores-
cence was documented in a series of fluorescence photomicro-
graphs for each sample and time point using a Leitz DMR
binocular fluorescence microscope fitted with a Leica MPS 48/52
photoautomat attachment (Zeiss, Germany).
Rhodamine 123 release
Rhodamine 123 release as an indicator of mitochondrial impair-
ment and early onset of apoptosis (Yang et al, 1997) was examined
using a fluorescence-based 96-well plate assay, following a
procedure described previously (Burger et al, 1995). Effects were
measured up to 8 h of exposure to IC50 and TGI concentrations of
C1311.
DNA binding – thermal denaturation studies
C1311 was subjected to DNA melting studies with calf thymus
DNA at a fixed concentration of 50 mM(bp) by adaptation of a
reported procedure (McConnaughie and Jenkins, 1995). Working
solutions containing CT-DNA and the test compound (2–50 mM)
were prepared by addition of concentrated drug solutions in
DMSO, to give defined [drug]/[DNA(bp)] molar ratios in the
0.04–1.00:1 range. Samples were monitored at 260 nm using a
Varian-Cary 1E spectrophotometer fitted with a Peltier heating
accessory. Heating was applied at 1°C min–1 in the 5–98°C range.
Optical data were imported into the Origin 5.0 computer package
(MicroCal Inc., Northampton, MA, USA) for analysis, and DNA
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Figure 1 Structure of the imidazoacridinone C1311, daag = diaminoalkyl
grouphelix®coil transition temperatures (Tm) were obtained from the
maxima in the d(A260)/dT derivative plots. Results are given as the
mean ± s.d. from three determinations and are corrected for the
effects of DMSO cosolute using a linear correction term
(McConnaughie and Jenkins, 1995). Drug-induced alterations in
DNA melting behaviour are given by: ÆTm = Tm(DNA + drug) –
Tm(DNA alone), where the Tm value for the drug-free CT-DNA is
67.8 ± 0.1°C. The [drug]/[DNA] ratios used did not result in
binding saturation of the host DNA duplex.
DNA binding – optical titration experiments
Equilibrium binding constants were determined by spectrophoto-
metric titration of a solution of C1311 (100 mM) with serial
aliquots (0.5–5 ml) of concentrated CT-DNA (~8.8 mM in bp) at
25.0 ± 0.1°C using a published procedure (Jenkins, 1997). After
each addition and equilibration for 5 min, the absorption spectrum
(700–220 nm) was recorded using a Varian-Cary 1E instrument.
Addition of aliquots continued until the decreased visible
absorbance at 425 nm for the free drug became constant, at which
point the addition of DNA itself causes a slight increase. The
optical characteristics for binding are as follows: lmax(free/
bound) = 425/430 nm, isosbestic points at 314/335/476 nm. The
optical changes at the lmax values were analysed to determine the
equilibrium distribution of free and bound drug molecules at each
data point. The intrinsic DNA–drug equilibrium binding constant
Ki was calculated using the following relationship (McGhee and
von Hippel, 1974):
where r is the mole ratio of bound drug to total DNA sites, Cf is the
concentration of free ligand and n is the neighbour exclusion para-
meter or binding site size (Chaires et al, 1982; Jenkins, 1997).
Values for Ki and n were determined from binding isotherms using
a non-linear fitting routine with the Kaleida Graph 3.08 program
(Synergy Software, Reading, PA, USA).
DNA binding – viscometric studies
Viscosity experiments were carried out in an Ostwald-type capil-
lary viscometer maintained at 25.0 ± 0.1°C by immersion in a
circulating water bath (Pilch et al, 1993; Suh and Chaires, 1995).
Aliquots of concentrated drug solution were added directly to the
viscometer containing a CT-DNA solution [1.3 ml of 250 mM(bp)]
in phosphate buffer to give [total drug]/[DNA(bp)] molar ratios of
0.075, 0.15, 0.225 and 0.30. These values were selected on the
basis of the binding isotherms obtained from the optical titration
experiments. Control experiments were performed with Hoechst
33258 dye, an established DNA minor groove-binding ligand
(Loontiens et al, 1990; Quintana et al, 1991; Haq et al, 1997).
After mixing by bubbling with a N2 gas stream and thermal
equilibration for 30 min, flow times were measured in triplicate to
an accuracy of ± 0.1 s; averaged data were used for analysis. For
the viscometer used, flow times in the range of 160–220 s were
measured after each addition of C1311 ligand. Relative viscosity
values were calculated from the observed flow times (t) of DNA-
containing solutions corrected for the flow time of the buffer alone
(t0), using the relation h = (t – t0)/t0. Data are presented as (h/h0)1/3
versus the experimental binding ratio, where h0 is the viscosity of
the drug-free DNA solution. This factor approximates to the ratio
of relative DNA contour lengths, L/L0, where L and L0 represent
the lengths of the rod-like duplex molecule in the presence and
absence of added drug.
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Table 1 Effects of drug concentration (C) and time (T) on chemosensitivity
in HT29 cells
Exposure time (h) C´T value required to kill 50% of cells
(mM h-1) ± s.e.m.
1 5.0  ± 0.1
4 3.9  ± 0.05
24 0.39 ± 0.01
144 0.36 ± 0.08
r = Ki(1 – nr) 1–   nr n – 1
Cf 1 – (n – 1)r
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Figure 2 (A) Reversibility of drug effect determined at IC50 (n n) and TGI
(n n) concentrations of C1311 as compared to vehicle-treated control
cells (n n), 100% O.D. = 1.25 ± 0.05 (B). C1311/DNA complex formation after
1 h, 4 h and 8 h exposure to C1311 at IC50 (0.5 mM) and TGI (2 mM)
concentration in comparison to vehicle-treated control (C) cells. Dotted line
indicates non-specific background
[]Cytosolic preparations and determination of acid
phosphatase activity
Ten million exponentially growing HT29 cells, either untreated
(control) or treated with C1311 at concentrations of 0.5 mM and
2.0 mM for 2, 8 or 24 h, were washed twice with ice-cold PBS and
homogenized in 0.5 ml of PBS using Kontes tubes. The cell
homogenates were spun in a Beckman Optima TL ultracentrifuge
at 600 g/4°C for 10 min and then, after removal of the supernatant,
at 15 000 g/4°C for 15 min. The supernatant was separately
centrifuged at 105 000 g/4°C for 1 h to obtain a cytosolic prepara-
tion/cell sap.
Acid phosphatase activity was determined in HT29 cytosolic
preparations by using the Sigma Diagnostics Phosphatases kit
according to the supplied instruction. In brief: 4-nitrophenyl phos-
phate in citrate buffer (pH 4.8) was used as substrate and pre-
warmed to 37°C, then 0.2 ml of cytosol or water (negative control)
was added and the mixture incubated at 37°C for 30 min. The
reaction was stopped with 5 ml 0.1 M sodium hydroxide and the
absorbance was measured at 420 nm using a Beckman DU 650
spectrophotometer. Acid phosphatase units for any individual
sample were determined from a calibration curve.
Apoptosis assay
Exponentially growing HT29 cells on cover slips were treated
with 2 mM C1311 for 2, 4, 8 and 24 h. Untreated cells were used as
negative control for each time point and another set treated with
40 mM for 48 h to ensure cell death. After each treatment interval,
slides were washed with PBS, air dried and cells fixed with 4%
formaldehyde in PBS for 30 min. After washing with PBS, cells
were subjected to a TUNEL assay using an ApopTag® (S7101 kit,
Appligene Oncor, Watford, UK), according to the manufacturer’s
instructions. Slides were prepared and examined microscopically
and the extent of apoptosis was determined from the appearance of
peroxidase-labelled apoptotic bodies.
DNA fragmentation
Exponentially growing HT29 colon cancer cells were cultured in
the presence of either 2 mM C1311 (TGI) for 2, 8 and 24 h or 50 mM
etoposide (positive control) for 8 h respectively. DNA from
5  ´ 106 cells was extracted and analysed following an established
protocol (Beckwith et al, 1993). All experiments were performed
at least in triplicate.
RESULTS
In vitro cytotoxicity and intracellular distribution of
C1311
Since C1311 had demonstrated potent in vivo anti-tumour activity
in the HT29 human colon cancer xenograft model (Burger et al,
1996), we used this cell line to investigate the mechanism(s) of
C1311 antiproliferative activity in intact cells. Cell kinetics studies
were performed to determine whether there is a concentration–
time dependency (C´T) for the cytotoxic effects of C1311 at IC50
and TGI concentrations. The response of HT29 cells to different
schedules of C1311 showed no notable differences in cytotoxicity
between a 1 h and 4 h exposure period, with C´T values to achieve
50% cell kill of 5.0 and 3.9 mM h–1 respectively. However, treat-
ment with C1311 for 24 h was approximately ten times more
effective such that the C´T parameter was closely similar to the 6-
day value for continuous exposure (Table 1).
In contrast, drug concentrations inducing total growth inhibition
(TGI) in a 6-day proliferation assay were already deleterious to
HT29 cells after only 1 h of incubation (Figure 2A). This effect on
tumour cell growth was paralleled by formation of measurable
DNA/C1311 complexes in HT29 cells which reached a maximum
at 1-h exposure to TGI doses (Figure 2B). The short period (up to
8 h) of drug reversibility at IC50 and the rapid manifestation of
cytotoxic lesions and measurable DNA/C1311 complexes at the
TGI concentration of C1311 indicate the involvement of a DNA-
interactive mode of action for this drug.
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Figure 3 (A) C1311 uptake in HT29 colon cancer cells. (B) Labelling of HT29 cells with the lysosomal marker dye Lyso TrackerTM. (C) Staining pattern in HT29
cells with the mitochondrial membrane probe rhodamine 123. Comparison is shown for dye localization after 30 min exposure to C1311. Magnification 570 ´Indeed, by following the cellular distribution of inherent C1311
fluorescence we observed a rapid localization of drug in the nuclei
of cancer cells (Figure 3A), as noted previously (Berger et al, 1996;
Burger et al, 1996; Skladanowski et al, 1996). However, nuclear
fluorescence was also accompanied by punctate accumulation in
cytosolic organelles and, although cytoplasmic localization was
reported earlier (Berger et al, 1996; Burger et al, 1996), its role in
C1311 induced tumour growth inhibition remained unclear. The
structural features of C1311 suggested to us that the compound
would not only be capable of binding to DNA, but may also be
trapped into acidic cell compartments due to its basic nature. Thus,
due to their protonatable daag side-chains (Figure 1), imidazo-
acridinones are likely to accumulate in the lysosomes that provide
the most acidic cellular structures. To test this hypothesis, the local-
ization of lysosomal and mitochondrial marker dyes was compared
to C1311. Lyso trackerTM showed the same cellular distribution
pattern as the C1311 cytosolic concentration (Figure 3A vs 3B),
whilst Mito tracker™ or rhodamine 123 (Figure 3A vs 3C) did not
match the picture. By studying rhodamine 123 release under C1311
treatment, no effect on mitochondrial membrane integrity was
observed (data not shown). The fact that mitochondria were not
stained by C1311 and mitochondrial membrane remained intact for
more than 8 h under C1311 exposure suggests that these organelles
were not targeted. These observations are important in view of
current understanding that mitochondria play a pivotal role in
controlling cell death in as much that cytochrome C release from
mitochondrial membranes is thought to be the initial stimulus of
apoptosis cascades (Yang et al 1997; Green and Reed, 1998).
Moreover, following uptake of C1311 in HT29 cells over a time
course of 24 h, drug even appeared to migrate from the nuclear
compartment into the lysosomes. Lysosomes were markedly
enlarged at 8 h under continuous exposure to C1311 and some
diffuse cytoplasmic fluorescence resulting from free drug became
evident (Figure 4A). Twenty-four hours after drug addition,
rupture of ‘mega’ lysosomes was observed, with C1311 leaking
out of these compartments (Figure 4B).
C1311-induced lysosomal rupture correlates with
increase in acid phosphatase activity
Acid phosphatase activity was measured as marker enzyme to
examine C1311 lysosomotropism and the resulting lysosomal
rupture described above. Enzyme activity was determined 2, 8 and
24 h after exposure to the drug. No difference between control and
C1311-treated HT29 cells was seen at 2 h, and no lysosomal
rupture was evident at this time point. At 8 h, when the lysoso-
motropic effect was very prominent, increased acid phos-
phatase activity was noted in HT29 cells treated at the TGI
concentration with 3.03 ± 0.01 U ml–1 as compared to a value of
2.17 ± 0.12 U ml–1 for the untreated control cells. A significant
change to 5.31 ± 0.09 U ml–1 was found for cells after treatment
Cellular and DNA mechanisms of C1311 371
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Figure 4 C1311 accumulation in the lysosomes of HT29 cells. (A) Enlargement of lysosomes (white arrowhead) 8 h after exposure to the TGI concentration
(2 mM). (B) Most of the drug has migrated into the lysosomes and rupture of lysosomes is apparent (white arrowhead) 24 h after continuous exposure to C1311.
Magnification 780 ´
Figure 5 Acid phosphatase activity in the cytoplasm of HT29 cells untreated
(n n) or treated with C1311 at TGI concentrations for 8 h ( ) and 24 h ( )
respectively. *P < 0.05 (Student’s t-test)with C1311 for 24h, reflecting the severe lysosomal rupture and
collapse of these organelles (Figure 5). However, changes in acid
phosphatase activity were not evident for the HT29 cells at IC50
concentrations.
Thermal denaturation studies, binding affinity and
stoichiometry
C1311 was assessed as a DNA-binding agent by determination of
the thermal helix®coil or melting stabilization (ÆTm) afforded to
duplex-form calf thymus DNA. This pseudo-random DNA was
selected to overcome possible limitations due to base sequence-
dependent binding effects. The compound induced significant
stabilization of the DNA duplex relative to the melted strands;
Table 2 shows the C1311-induced ÆTm shifts. Analysis of the
differential effects (data not shown) induced upon the G/C or high-
temperature (i.e. T> Tm) portion of the DNA melting curve relative
to the A/T or low-temperature (i.e. T< Tm) region suggests possible
site- or sequence-preferential binding to AT-rich base segments
(McConnaughie and Jenkins, 1995). Factors of ~1.3 are evident
from the differential behaviours, particularly at higher [drug]/
[DNA] mole ratios where the host duplex is approaching drug satu-
ration. However, such observations can only be qualitative given
the thermodynamic limitations of this technique and must await
direct observations from sequence foot-printing experiments.
Spectrophotometric titration of calf thymus DNA with
C1311 yields an intrinsic binding constant for this interaction of
4.5 ´106 M(bp)–1 with a DNA-binding site size that spans 3.5 base
pairs (r= 0.993 for 25 data points). Taken together, these data
(Table 2) indicate strongly affinic binding for C1311 to the duplex,
with frequent binding sites for this random-sequence DNA.
Evidence for intercalative DNA binding mode
The criteria for establishing the mode of interaction for DNA
ligands have recently been reviewed, indicating that viscosity
measurements provide one of the few reliable indicators to distin-
guish intercalative and groove-mediated binding mechanisms (Suh
and Chaires, 1995). Attempted comparative studies of fluores-
cence quenching and displacement of ethidium bromide were
thwarted by the inherent fluorescence of the imidazoacridinone
compound C1311. Such indirect fluorometric techniques have
previously been used to determine ‘apparent’ binding constants
and qualitative information regarding the binding mechanism for
candidate ligands (McConnaughie and Jenkins, 1995; Jenkins,
1997). Thus, instead, we examined the effect of C1311 upon the
hydrodynamic properties of DNA.
Figure 6 shows the results from viscometric studies with calf
thymus DNA with increasing amounts of either C1311 or Hoechst
33258 for a [drug]:[DNA] range of 0–0.30:1 that corresponds to
non-saturating binding ratios established by titration spectro-
photometry. The established minor groove-binding ligand, Hoechst
33258, was used to provide a control for a non-intercalative DNA-
binding dye (Loontiens et al, 1990; Vega et al, 1994). For rod-like
DNA duplex of length L, viscosity is markedly sensitive to length
changes (proportional to L0). ‘Classical’ ligand intercalation would
be expected to increase the relative length of the host duplex as has
been demonstrated for a number of established intercalating mole-
cules (Suh and Chaires, 1995). Figure 6 shows that C1311 clearly
increases the relative contour length of double-stranded CT-DNA,
whereas the Hoechst dye effects only a negligible change in the drug
dose range examined. These data lead us to conclude that DNA
interaction by the imidazoacridinone C1311 involves an intercala-
tive binding mechanism. Further, given the size of the DNA binding
site (see above), comparison with established intercalating agents
and hybrid combilexin-type ligands suggests that the protonated
daag side-chain makes a snug fit into a helical conduit of the DNA
duplex (see, for example: Bailly et al, 1989; Agbandje et al, 1992).
Such groove accommodation would be expected to achieve
favourable electrostatic, hydrophobic and hydrogen-bonded
contacts with the host to further stabilize the binding process.
C1311 and apoptosis in HT29 colon cancer cells
Most anticancer drugs in current use induce apoptosis in suscep-
tible cells (Hickman, 1992). However, it is important to discern the
role of apoptosis and the timing of the onset of the cell death
cascade in relation to other cellular events. Using the HT29 cell
line we could not observe signs of apoptosis by means of impair-
ment of mitochondrial membrane potential (described earlier),
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Table 2Binding behaviour of C1311 to calf thymus DNA at pH 7.0
ÆTm (°C)a at [drug]/[DNA] ratio
Ki
b n c
0.04:1 0.1:1 0.2:1 0.4:1 1:1 (´106 M(bp)–1) (bp)
3.5 6.8 10.0 13.8 18.7 4.5 ±0.3 3.5 ±0.1
aDrug-induced thermal stabilization of CT-DNA (±< 0.2°C) for the [C1311]/[DNA(bp)] molar ratios shown. bIntrinsic binding constant determined from optical
titration with CT-DNA (see text). cBinding site size in DNA base pairs.
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Figure 6   Relative contour length of calf thymus DNA after addition of either
C1311 (l) or Hoechst 33258 (n) at the [total drug]/[DNA] ratio shown. The
control Hoechst dye, a non-intercalative groove-binding ligand, has little
effect whereas C1311 extends the contour length of duplex DNA, as
expected for an intercalating ligandDNA fragmentation by nick-labelling (ApopTag, Figure 7A) or
typifying ladder pattern (Figure 7B) prior to other effects seen
such as nuclear uptake of C1311 or lysosomal breakdown.
Apoptotic cells were easily identified after treatment with
suprelethal C1311 concentrations (40 mM approximately 20X TGI)
for 48 h, indicating a successful assay (Figure 7A, iii). We have
shown previously that DNA synthesis in HT29 cells is strongly
inhibited as early as 1 h after exposure to C1311 at TGI concentra-
tions (Burger et al, 1996), yet the onset of C1311-induced apop-
tosis in these cells is much delayed and does not occur before 24 h
of treatment (Figure 7B). This behaviour indicates that DNA inter-
calation alone would not cause the potent cytotoxicity seen for
C1311. Moreover, as lysosomal swelling is evident at 8 h of
continuous exposure to a TGI dose (Figure 4A) and severe rupture
is seen after 24 h (Figure 4B), it has to be considered that the apop-
tosis cascade is not mediated by C1311 directly, but may be trig-
gered indirectly by cell autolysis. In contrast, treatment of HT29
cells with etoposide, an agent known for inducing apoptosis at an
early point, resulted in a strong DNA ladder after 8 h of continuous
drug exposure (Figure 7B).
DISCUSSION
C1311 is a new investigational agent that will be evaluated for its
potential use in the treatment of colorectal cancer. Thus, to design
appropriate trial protocols, it is important to understand how an
agent modulates tumour cell growth. Although it is clear from
earlier work that DNA and complexes cleavable by topoisomerase
II are a cellular target of imidazoacridinone C1311 (Berger et al,
1996; Burger et al, 1996; Skladanowski et al, 1996), the precise
mode and strength of DNA binding has not been delineated. Drug
accumulation in other than the nuclear compartment, and the
cellular kinetics of drug action or the consequences leading to cell
death remained largely undefined.
The principal conclusions that can be drawn from this study are
as follows: (i) C1311 is a potent inhibitor of HT29 tumour cell
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Figure 7 (A) TUNEL (ApopTag) assay for HT29 cells grown on glass slides.
Untreated control (i) or treated for 24 h(bar = 20 mM) (ii) with TGI (i.e. 2 mM)
C1311 and stained for presence of apoptotic DNA nicks. Positive staining
can be seen in the cultures treated with 40 mM C1311 for 48 h (iii). (B)
Apoptotic DNA ladder. Genomic DNA was isolated from treated cells as
described, resolved on a 1.5% agarose gel and stained with ethidium
bromide. Lane 1, HT29 cells treated with C1311 at TGI concentration (2 mM)
for 2 h; lane 2, for 8 h; lane 3 for 24 h; lane 4, HT29 cells treated with
etoposide (50 mM) for 8 hgrowth. However, drug effects are schedule- and time-dependent,
such that C´T parameters will be an important consideration to
achieve clinical efficacy; (ii) C1311 binds to duplex DNA by inter-
calation, with a high affinity for random-sequence DNA; (iii) the
diaminoalkyl structural element also confers a basic nature to
C1311 that results in entrapment of the drug in the most acidic
cell compartments, the lysosomes (pH 4–5), by an interaction
described as acidic shift (Simon et al, 1994). This lysosomotro-
pism of C1311 leads to subsequent lysosomal swelling, rupture
and release of autolytic enzymes at concentrations relevant for
inhibition of tumour cell growth (Figures 4 and 5); (iv) lysosomal
rupture (8 h after treatment at the TGI dose) precedes the onset of
apoptosis (not prior to 24 h treatment at TGI) by the means of
DNA-fragmentation for more than 16 h (Figure 7). Thus, the lyso-
somal compartment is broken down and cell autolysis is initiated
before apoptosis becomes evident, indicating a central role for
induced lysosomal rather than DNA damage in the cascade of
C1311-mediated cell death.
Lysosomes and lysosomal enzymes have long been postulated to
play a role in cancer. It has been shown that the specific activity of
lysosomal enzymes in tumours is elevated as compared to normal
tissues. Indeed, shrinkage of neoplasms in response to therapy has
been attributed to lysosomes or their products (reviewed in Allison,
1974; Overgaard, 1977; Boyer and Tannock, 1993). In accord, de
Duve had proposed in the late 1950s that cells might be killed from
within, by an explosion of their lysosomes acting as ‘suicide bags’,
and thus that lysosomes may represent a possible target for thera-
peutic intervention (Majno and Joris, 1995). Although none of the
standard anticancer agents currently used in the clinic is thought to
kill tumour cells by affecting lysosomes, it has been described that
the efficacy of hyperthermia (Overgaard, 1977) and radiation
treatment is partly due to lysosomal breakdown and release of
lysosomal enzymes, e.g. acid phosphatase, b-glucuronidase and
cathepsin B, into the cytoplasm (Boyer and Tannock, 1993).
Furthermore, Firestone and co-workers proposed a novel approach
to target tumour cells by utilizing lysosomal enzymes and synthe-
sized a new class of agents termed lysosomotropic detergents
(Firestone et al, 1979). These compounds are designed to be
weakly basic so they concentrate within lysosomes as a result of the
pH gradient across the lysosomal membrane. Drug accumulating
inside the lysosomes would then dissolve the membranes, releasing
lysosomal enzymes into the cytoplasm and result in cell death from
autolysis. Furthermore, a similar concept was recently described
by Engelke and colleagues (Engelke et al, 1997). These authors
observed that 9-aza-anthrapyrazoles with tertiary amine side
chains, compounds structurally related to C1311, localized in lyso-
somes and proposed that they would act by a lysosomal mechanism
rather than DNA interaction.
Intercalation alone may not be sufficient for the marked anti-
tumour activity of C1311, and it has been established that the
subsequently formed cleavable DNA–protein complexes are
reversible and probably not the sole cause of cell death
(Skladanowski et al, 1996). Thus, the pronounced cytotoxic effects
exerted by C1311 toward tumour cells in vitro and in vivo may in
part result from induced lysosomal rupture and the cascade of
events leading to cell kill detailed above.
Our kinetic data and fluorescence drug uptake studies, which
show cytotoxic effects paralleled by lysosomal drug accumulation
and increased lysosomal enzyme activity starting at 8 h of drug
exposure, strongly support a lysosomal involvement in the mode
of action of C1311.
In conclusion, understanding the role of lysosomes in cancer and
targeting these cellular compartments in an anti-cancer strategy by
using them as ‘suicide bags’ warrants further investigation.
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